6 January 2022 in World Journal of Urology
1 January 2022 in Therapeutic Advances in Urology
Introduction: Partial nephrectomy (PN) is associated with a non-negligible risk of postoperative cardiovascular morbidity and mortality. Identification of high-risk patients may enable optimization of perioperative management and consideration of alternative approaches. The authors aim to develop a procedure-specific cardiovascular risk index for PN patients and compare its performance to the widely used revised cardiac risk index (RCRI) and AUB-HAS2 cardiovascular risk index. Methods: The cohort was derived from the American College of Surgeons – National Surgical Quality Improvement Program (ACS-NSQIP) database. The primary outcome was the incidence of major adverse cardiovascular events (MACE), defined as 30-day postoperative incidence of myocardial infarction, stroke, or mortality. A multivariate logistic regression model was constructed; performance and calibration were evaluated using an ROC analysis and the Hosmer–Lemeshow test and compared to the RCRI and the AUB-HAS2 index. Results: In a cohort of 4795 patients, MACE occurred in 52 (1.1%) patients. A univariate analysis yielded 13 eligible variables for entry into the multivariate model. The final PN-A4CH model utilized six variables: Age ⩾75 years, ASA class >2, Anemia, surgical Approach, Creatinine >1.5, and history of Heart disease. Index ROC analysis provided a C-statistic of 0.81, calibration R2 was 0.99, and sensitivity was 85%. In comparison, the RCRI and AUB-HAS2 C-statistics were 0.59 and 0.68, respectively. Conclusion: This study proposes a novel procedure-specific cardiovascular risk index. The PN-A4CH index demonstrated good predictive ability and excellent calibration using a large national database and may enable further individualization of patient care and optimization of patient selection.
10 January 2000 in American Journal of Hematology
We report here a case of ticlopidine‐induced aplastic anemia that responded to G‐CSF and review the literature. An 83‐year‐old woman was started on ticlopidine for coronary artery disease after an episode of upper gastrointestinal bleeding secondary to aspirin. She developed aplastic anemia seven weeks after initiation of ticlopidine. She was hospitalised and received empiric antibiotic therapy and granulocyte colony stimulating factor (G‐CSF). Her bone marrow started to recover quickly, and white blood cell and platelet counts returned to normal within three weeks. A review of medical literature revealed 20 similar cases of ticlopidine‐induced aplastic anemia resulting in death in seven cases. G‐CSF has been used previously with variable success. Ticlopidine is associated with serious, sometimes fatal hematological side effects. This risk should be seriously taken into consideration when prescribing ticlopidine. G‐CSF may be helpful in the treatment of ticlopidine‐induced aplastic anemia. Am. J. Hematol. 63:90–93, 2000.
4 March 2022 in European Journal of Obstetrics & Gynecology and Reproductive Biology
1 March 2025 in JU Open Plus
Purpose: The purpose of this study was to compare the impact of blue light cystoscopy (BLC) vs white light cystoscopy (WLC) on the oncologic outcomes of nonmuscle invasive bladder cancer (NMIBC). Materials and Methods: We identified patients diagnosed with NMIBC between 1997 and 2021 in the Veterans Affairs Healthcare System. A 1:1 propensity score matching algorithm was used, accounting for baseline demographic and clinical variables. The primary objective was to determine recurrence and progression-free survival, using multivariable Cox proportional hazards regression models. Results: Among 626 matched patients (313 BLC and 313 WLC), median age at diagnosis was 71 years, 616 (98%) were male, 381 (61%) were high-risk NMIBC, and 159 (25%) had bladder cancer recurrence. Median follow-up was 3.7 years. Recurrence risk at 3 years was significantly reduced after BLC vs WLC (hazard ratio = 0.62; 95% confidence interval, 0.45-0.86; P < .01). Progression risk at 3 years was reduced; however, this was not statistically significant (hazard ratio = 0.71; 95% confidence interval, 0.37-1.38; P = .32). Compared with WLC patients, BLC patients were significantly more likely to receive intravesical Bacillus Calmette-Guerin (61% vs 43%; P < .01) or intravesical chemotherapy (48% vs 27%, P < .01). No difference in definitive treatment rates (radical cystectomy, radiation therapy, and/or systemic chemotherapy) was observed (8% vs 6%; P = .27) between BLC and WLC patients. Conclusions: In a high-risk NMIBC predominant cohort, the use of BLC was associated with reduced risk of bladder cancer recurrence. BLC use was also associated with increased use of intravesical therapies but not definitive treatment. These findings provide evidence for the oncologic benefits of using BLC.